by Tom Emerick
First posted on Cracking Health Costs on 01/29/2013
A WSJ article by Peter Loftus says, “Merck & Co. pulled its cholesterol drug Tredaptive from markets world-wide after a patient study showed it failed to reduce the risk of heart-related problems and was associated with safety risks.” Click here to read the full article.
Further, “An advisory committee to the European Medicines Agency recommended the suspension of the drug’s availability after concluding its risks were greater than the benefits, the EMA said Friday.”
This is another in a long list of drugs, usually very expensive ones, seemingly rushed to market but which in the end prove to be either useless or harmful to patients.
It looks like the US dodged this one as the FDA refused to approve this drug pending clinical testing.
Tom Emerick is the President of Emerick Consulting, LLC, and Partner and Chief Strategy Officer with Laurus Strategies, a Chicago-based consulting firm. Prior to starting his consulting career, Tom was with Walmart Stores, where his last position was Vice President, Global Benefit Design, which involved designing and managing benefits for over 1.3 million employees in the U.S., and 300,000 plus in international. For about six years, Tom also headed up Walmart’s Six Sigma and process improvement initiatives. Prior to Walmart, Tom had positions with Burger King Corporation, British Petroleum, and American Fidelity Assurance Company. In 2009, Tom was named by Healthspottr as one of the top 100 innovators in healthcare the US for his work on medical ethics. In December 2012, Tom was listed in Forbes.com as one of 13 unsung heroes changing healthcare forever.